Pharmacokinetic Evaluation and Exploration of Antifungal Activity of Synthesized Pyrazole-Based Compounds

The synthesized pyrazole-based compounds were evaluated for their pharmacokinetic properties and antifungal activity. The pharmacokinetic results, obtained through the pKCSM server, showed favorable solubility, human intestinal absorption (HIA) greater than 70%, and good permeability to the central nervous system (CNS) for certain compounds, with low inhibition of CYP450 enzymes and predicted toxicity within safe limits. Regarding antifungal activity, the compounds demonstrated effective inhibition of the growth of two pathogenic fungi, with minimum inhibitory concentrations (MIC) ranging from 2 to 16 µg/mL. These results suggest that these compounds possess an optimal pharmacokinetic profile and promising antifungal activity, making them attractive candidates for clinical development. Thus, this study identifies compounds with high therapeutic potential for the treatment of fungal infections while ensuring a good safety profile for future development.